357 related articles for article (PubMed ID: 30529590)
1. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
Rinella ME; Trotter JF; Abdelmalek MF; Paredes AH; Connelly MA; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Harrison SA
J Hepatol; 2019 Apr; 70(4):735-744. PubMed ID: 30529590
[TBL] [Abstract][Full Text] [Related]
2. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
3. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R
Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502
[TBL] [Abstract][Full Text] [Related]
4. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Rossi SJ; Paredes AH; Trotter JF; Bashir MR; Guy CD; Banerjee R; Jaros MJ; Owers S; Baxter BA; Ling L; DePaoli AM
Hepatology; 2020 Apr; 71(4):1198-1212. PubMed ID: 30805949
[TBL] [Abstract][Full Text] [Related]
5. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
[TBL] [Abstract][Full Text] [Related]
6. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
[TBL] [Abstract][Full Text] [Related]
7. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
Newsome PN; Palmer M; Freilich B; Sheikh MY; Sheikh A; Sarles H; Herring R; Mantry P; Kayali Z; Hassanein T; Lee HM; Aithal GP;
J Hepatol; 2020 Aug; 73(2):231-240. PubMed ID: 32234329
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
[TBL] [Abstract][Full Text] [Related]
10. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis.
Zhou M; Learned RM; Rossi SJ; Tian H; DePaoli AM; Ling L
J Lipid Res; 2019 Mar; 60(3):550-565. PubMed ID: 30679232
[TBL] [Abstract][Full Text] [Related]
12. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
13. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
14. [EFFICIENCY OF CONCOMITANT USE OF POLICOSANOL AND ROSUVASTATIN IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE AND MODERATE HEPATIC DYSFUNCTION].
Solomenchuk TM; Vosukh V; Bedzay A; Koval VG; Chepka IM; Trotsko VV
Lik Sprava; 2015; (7-8):29-37. PubMed ID: 27491147
[TBL] [Abstract][Full Text] [Related]
15. Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.
Saeedi R; Johns K; Frohlich J; Bennett MT; Bondy G
Lipids Health Dis; 2015 Jun; 14():57. PubMed ID: 26087958
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis.
Männistö VT; Simonen M; Soininen P; Tiainen M; Kangas AJ; Kaminska D; Venesmaa S; Käkelä P; Kärjä V; Gylling H; Ala-Korpela M; Pihlajamäki J
J Lipid Res; 2014 Dec; 55(12):2676-84. PubMed ID: 25344588
[TBL] [Abstract][Full Text] [Related]
17. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH.
Loomba R; Ling L; Dinh DM; DePaoli AM; Lieu HD; Harrison SA; Sanyal AJ
Hepatology; 2021 Jan; 73(1):126-143. PubMed ID: 32794259
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
[TBL] [Abstract][Full Text] [Related]
19. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
[TBL] [Abstract][Full Text] [Related]
20. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
